AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

American Journal of Public Health, Vol. 75, Issue 7 739-744, Copyright © 1985 by American Public Health Association

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by White, C C
Right arrow Articles by Orenstein, W A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by White, C C
Right arrow Articles by Orenstein, W A
Benefits, risks and costs of immunization for measles, mumps and rubella.

C C White, J P Koplan and W A Orenstein

For a single year, 1983, we compared the actual and estimated morbidity, mortality, and costs attributable to measles, mumps, and rubella with having or not having a childhood immunization program using the combined measles-mumps-rubella (MMR) vaccine. Without an immunization program, an estimated 3,325,000 cases of measles would occur as compared to 2,872 actual cases in 1983 with a program. Instead of an expected 1.5 million rubella cases annually, there were only 3,816 actual cases. Mumps cases were lowered from an expected 2.1 million to 32,850 actual cases. Comparable reductions in disease-associated complications, sequelae, and deaths are gained with an immunization program. Without a vaccination program, disease costs would have been almost $1.4 billion. Based on the actual incidence of disease in 1983, costs were estimated to be approximately +14.5 million. Expenditures for immunization, including vaccine administration costs and the costs associated with vaccine reactions, totaled $96 million. The resulting benefit-cost ratio for the MMR immunization program is approximately 14:1. The savings realized due to the use of combination rather than single antigen vaccine total nearly $60 million.




This article has been cited by other articles:


Home page
 Arch Pediatr Adolesc MedHome page
F. Zhou, J. Santoli, M. L. Messonnier, H. R. Yusuf, A. Shefer, S. Y. Chu, L. Rodewald, and R. Harpaz
Economic Evaluation of the 7-Vaccine Routine Childhood Immunization Schedule in the United States, 2001
Arch Pediatr Adolesc Med, December 1, 2005; 159(12): 1136 - 1144.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
G. H. Dayan, I. R. Ortega-Sanchez, C. W. LeBaron, M. P. Quinlisk, and and the Iowa Measles Response Team
The Cost of Containing One Case of Measles: The Economic Impact on the Public Health Infrastructure--Iowa, 2004
Pediatrics, July 1, 2005; 116(1): e1 - e4.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
Y. Lotan, J. A. Cadeddu, J. J. Lee, C. G. Roehrborn, and S. M. Lippman
Implications of the Prostate Cancer Prevention Trial: A Decision Analysis Model of Survival Outcomes
J. Clin. Oncol., March 20, 2005; 23(9): 1911 - 1920.
[Abstract] [Full Text] [PDF]

Home page
 Nurs EthicsHome page
J. Wood-Harper
Informing Education Policy on MMR: balancing individual freedoms and collective responsibilities for the promotion of public health
Nursing Ethics, January 1, 2005; 12(1): 43 - 58.
[Abstract] [PDF]

Home page
 DTBHome page
MMR vaccine - how effective and how safe?
DTB, April 1, 2003; 41(4): 25 - 29.
[Abstract] [Full Text] [PDF]

Home page
 Epidemiol RevHome page
A. J. Vyse, N. J. Gay, J. M. White, M. E. Ramsay, D. W. G. Brown, B. J. Cohen, L. M. Hesketh, P. Morgan-Capner, and E. Miller
Evolution of Surveillance of Measles, Mumps, and Rubella in England and Wales: Providing the Platform for Evidence-based Vaccination Policy
Epidemiol. Rev., December 1, 2002; 24(2): 125 - 136.
[Full Text] [PDF]

Home page
 PediatricsHome page
A. Makela, J. P. Nuorti, and H. Peltola
Neurologic Disorders After Measles-Mumps-Rubella Vaccination
Pediatrics, November 1, 2002; 110(5): 957 - 963.
[Abstract] [Full Text] [PDF]

Home page
 Int J EpidemiolHome page
K E Fullerton and S E Reef
Commentary: Ongoing debate over the safety of the different mumps vaccine strains impacts mumps disease control
Int. J. Epidemiol., October 1, 2002; 31(5): 983 - 984.
[Full Text] [PDF]

Home page
 JAMAHome page
H. Peltola, I. Davidkin, M. Paunio, M. Valle, P. Leinikki, and O. P. Heinonen
Mumps and Rubella Eliminated From Finland
JAMA, November 22, 2000; 284(20): 2643 - 2647.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
R. J. Jacobs, H. S. Margolis, and P. J. Coleman
The Cost-effectiveness of Adolescent Hepatitis A Vaccination in States With the Highest Disease Rates
Arch Pediatr Adolesc Med, August 1, 2000; 154(8): 763 - 770.
[Abstract] [Full Text] [PDF]

Home page
 American Journal of Medical QualityHome page
R. Armstead and D. Leong
Outcomes Improvement: The True Mark of Quality in Managed Care
American Journal of Medical Quality, September 1, 1999; 14(5): 202 - 210.
[Abstract] [PDF]

Home page
 NEJMHome page
J. C. Wright and M. C. Weinstein
Gains in Life Expectancy from Medical Interventions -- Standardizing Data on Outcomes
N. Engl. J. Med., August 6, 1998; 339(6): 380 - 386.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
F T Cutts and R Steinglass
Should measles be eradicated?
BMJ, March 7, 1998; 316(7133): 765 - 767.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by the American Public Health Association